Pharmafile Logo
Pharmafocus logo
Advanced Search
department-of-health-social-care

Government issues first serious shortage protocol to combat lack of the antidepressant fluoxetine

October 3, 2019
Manufacturing and Production

The Department of Health and Social care has brought in measures to allow pharmacists to supply alternative strengths of fluoxetine …

News

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis

October 3, 2019
Research and Development

Novartis has announced positive data from its PREVENT trial, which evaluated the safety and efficacy of Cosentyx (secukinumab) for patients …

News
sandrock-al-e1548286908776

Biogen announces leadership updates

October 2, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Biogen have announced updates to it senior leadership team with Alfred Sandrock being named Executive Vice President of Research and …

Appointment
opdivo_1_1

BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma

October 2, 2019
Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma

Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …

News
invokana

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

October 2, 2019
Research and Development

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the …

News

AstraZeneca strikes global commercial rights deal for $243m

October 2, 2019
Research and Development

Cambridge-headquartered AstraZeneca have agreed to sell certain global commercial rights for its Losec brand, in a deal that is worth …

News
gsk_boronia_australia

GSK’s Zejula slows disease progression in a range of ovarian cancers

October 2, 2019
Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma

At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …

News
jj_sign_on_wall

Johnson & Johnson settle opioid lawsuits in Ohio for $20m

October 2, 2019
Research and Development

Johnson & Johnson have agreed to settle opioid litigation with two Ohio counties for roughly $20.4 million in a deal …

News
dave_peacock

MSD announce David Peacock as new Managing Director in UK and Ireland

October 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

MSD have announced that David Peacock will become Managing Director in the UK and Ireland, succeeding former director Louise Houson, …

Appointment

Sanofi’s Jevtana doubles progression-free survival in metastatic castration-resistant prostate cancer

October 1, 2019
Manufacturing and Production, Research and Development ESMO 2019, Jevtana, Sanofi, pharma, prostate cancer

Sanofi was present at the 2019 European Society of Medical Oncology (ESMO) Congress in Barcelona this year to reveal new …

News

Chris Whitty begins role as England’s Chief Medical Officer

October 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

London consultant and public health professor, Chris Whitty, has begun his role as England’s Chief Medical Officer, taking over from …

Appointment
roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

News
lynparza

AZ and MSD’s parp inhibitor Lynparza cuts risk of progression and death in prostate cancer

October 1, 2019
Manufacturing and Production

AstraZeneca and MSD have shown in their Phase 3 PROfound trial, PARP inhibitor Lynparza (olaparib) reduced the risk of disease …

News
Sobi Logo

Sobi to acquire Dova for $915m to broaden hematology franchise

October 1, 2019
Manufacturing and Production

Sobi is to buy Dova Pharmaceuticals for $915 million in a bid to grow Sobi’s hematology portfolio, with liver cancer …

News
10257-itokwqzqhdt9

ESMO studies show CD4K/6 inhibitor and fulvestrant improves OS in breast cancer

October 1, 2019
Manufacturing and Production

Detailed findings from two Phase III trials presented at the European Society for Medical Oncology showed that treatment with a …

News
albert_bourla2019_300x170_1

Pfizer CEO Albert Bourla to Succeed Ian Read as Executive Chairman

September 30, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Pfizer’s executive chairman Ian Read, is to be succeeded by CEO Albert Bourla with a date to start the post …

Appointment
shutterstock

The world needs a better plan for cancer survival by 2030

September 30, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharma

Beginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …

Feature
astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …

News
merck-keytruda

MSD’s Keytruda meets primary endpoint in triple-negative breast cancer

September 30, 2019
Sales and Marketing

MSD have announced results from its Phase 3, KEYNOTE-522 trial that pathological complete response (pCR) in patients with early triple-negative …

News

Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis

September 30, 2019
Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis

Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026